temozolomide has been researched along with Hyperprolactinaemia in 3 studies
Excerpt | Relevance | Reference |
---|---|---|
"We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 7.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
"We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal." | 3.78 | Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. ( Barlier, A; Barrie, M; Brue, T; Castinetti, F; Conte-Devolx, B; Dufour, H; Morange, I; Philippon, M; Taieb, D, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Wildemberg, LE | 1 |
Fialho, C | 1 |
Gadelha, MR | 1 |
Bilbao, I | 1 |
Egaña, N | 1 |
García, C | 1 |
Olaizola, I | 1 |
Philippon, M | 1 |
Morange, I | 1 |
Barrie, M | 1 |
Barlier, A | 1 |
Taieb, D | 1 |
Dufour, H | 1 |
Conte-Devolx, B | 1 |
Brue, T | 1 |
Castinetti, F | 1 |
1 review available for temozolomide and Hyperprolactinaemia
Article | Year |
---|---|
Prolactinomas.
Topics: Antineoplastic Agents, Alkylating; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agon | 2021 |
2 other studies available for temozolomide and Hyperprolactinaemia
Article | Year |
---|---|
Failure of a second temozolomide cycle in a patient with a prolactin-secreting pituitary carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bromocriptine; Cabergoline; Combined | 2017 |
Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Cranial Irradiation; Dacarbazine | 2012 |